A Short Enantioselective Synthesis of (S)-Levetiracetam through Direct Palladium-Catalyzed Asymmetric N-Allylation of Methyl 4-Aminobutyrate

Abstract

An exceedingly short and enantioselective synthesis of the antiepileptic drug (S)-levetiracetam was elaborated. As the chirogenic key step, a Pd-catalyzed asymmetric N-allylation of methyl 4-aminobutyrate was achieved in the presence of only 1 mol% of a catalyst prepared in situ from [Pd(allyl)Cl]₂ and a tartaric acid-derived C ₂-symmetric diphosphine ligand.

Key words

asymmetric catalysis - palladium catalysis - chiral ligands - amino acid derivatives - ozonolysis - levetiracetam

Publication History

Received: 07 April 2021

Accepted after revision: 28 April 2021

Accepted Manuscript online:
28 April 2021

Article published online:
11 May 2021

• References and Notes

• 1a Sander JW. A. S, Shorvon SD. J. Neurol., Neurosurg. Psychiatry 1996; 61: 433
• 1b Kwan P, Brodie MJ. Expert Rev. Neurother. 2006; 6: 397
• 2a Ben-Menachem E. Expert Opin. Pharmacother. 2003; 4: 2079
• 2b Leeman BA, Cole AJ. Annu. Rev. Med. 2008; 59: 503
• 2c Ulloa CM, Towfigh A, Safdieh J. Neuropsychiatr. Dis. Treat. 2009; 5: 467
• 3a Cossement E, Motte G, Geerts J.-P, Gobert J. GB 2225322, 1992
• 3b Das Sarma K, Zhang J, Huang Y, Davidson JG. Eur. J. Org. Chem. 2006; 3730
• 3c Tucker JL, Xu L, Yu W, Scott RW, Zhao L, Ran N. WO 2009009117, 2009
• 3d Tang X.-L, Lu X.-F, Wu Z.-M, Zheng R.-C, Zheng YG. J. Biotechnol. 2018; 266: 20
• 3e Mylavarapu R, Anand RV, Kondaiah GC. M, Reddy LA, Reddy GS, Roy A, Bhattacharya A, Mukkanti K, Bandichhor R. Green Chem. Lett. Rev. 2010; 3: 225
• 4a Boschi F, Camps P, Comes-Franchini M, Muñoz-Torrero D, Ricci A, Sánchez L. Tetrahedron: Asymmetry 2005; 16: 3739
• 4b Kotkar SP, Sudalai A. Tetrahedron Lett. 2006; 47: 6813
• 5a Chandra Babu K, Buchi Reddy R, Mukkanti K, Suresh K, Madhusudhan G, Nigam S. J. Chem. 2013; 176512 DOI: 10.1155/2013/176512.
• 5b Raju V, Somaiah S, Sashikanth S, Laxminarayana E, Mukkanti K. Drug Invent. Today 2014; 6: 32
• 6a Surtees J, Marmon V, Differding E, Zimmermann V. WO 2001064637, 2001
• 6b Friedfeld MR, Zhong H, Ruck RT, Shevlin M, Chirik PJ. Science 2018; 360: 888
• 6c Zhong H, Friedfeld MR, Camacho-Bunquin J, Sohn H, Yang C, Delferro M, Chirik PJ. Organometallics 2019; 38: 149
• 7a Dohmen S, Reiher M, Albat D, Akyol S, Barone M, Neudörfl JM, Kühne R, Schmalz H.-G. Chem. Eur. J. 2020; 26: 3049
• 7b Albat D, Neudörfl J.-M, Schmalz H.-G. Eur. J. Org. Chem. 2021; 2099
• 8 Narczyk A, Mrozowicz M, Stecko S. Org. Biomol. Chem. 2019; 17: 2770
• 9a Wender PA, Verma VA, Paxton TJ, Pillow TH. Acc. Chem. Res. 2008; 41: 40
• 9b Wender PA, Miller BL. Nature 2009; 460: 197

For selected reviews, see:
• 10a Trost BM, Van Vranken DL. Chem. Rev. 1996; 96: 395
• 10b Trost BM, Crawley ML. Chem. Rev. 2003; 103: 2921
• 10c Graening T, Schmalz H.-G. Angew. Chem. Int. Ed. 2003; 42: 2580
• 10d Grange RL, Clizbe EA, Evans AA. Synthesis 2016; 48: 2911 ; and references cited therein
• 11a Trost BM, Calkins TL, Oertelt C, Zambrano J. Tetrahedron Lett. 1998; 39: 1713
• 11b Humphries ME, Clark BP, Williams JM. Tetrahedron: Asymmetry 1998; 9: 749
• 11c Tosatti P, Horn J, Campbell AJ, House D, Nelson A, Marsden SP. Adv. Synth. Catal. 2010; 352: 3153
• 12 Dindaroğlu M, Akyol Dinçer S, Schmalz H.-G. Eur. J. Org. Chem. 2014; 4315
• 13 Marshall JA, Garofalo AW, Sedrani RC. Synlett 1992; 643
• 14 Ates C, Surtess J, Burteau A.-C, Marmon V, Cavoy E. US 2004/0204476, 2004

CCDC 2074847 contains the supplementary crystallographic data for (S)-levetiracetam (1). The data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/structures. For earlier X-ray crystal structures of 1 determined at room temperature, see:
• 15a Song J, Lou K.-X, Li X.-J, Wua X.-P, Feng R.-X. Acta Crystallogr., Sect. E: Struct. Rep. Online 2003; 59: o1772
• 15b Bebiano SS, ter Horst JH, Oswald ID. H. Cryst. Growth Des. 2020; 20: 6731 ; (Structure determined at high pressure to investigate pressure-dependent polymorphism)
• 16 Detailed experimental procedures and characterization data are given in the Supporting Information. 1-[(2E)-1-Ethylpent-2-en-1-yl]pyrrolidin-2-one (2) Under an atmosphere of argon, a Schlenk flask was charged with [Pd(allyl)Cl]₂ (1.10 mg, 3.01 μmol, 0.50 mol%) and ligand L* (5.40 mg, 7.04 μmol, 1.17 mol%). Anhyd THF (0.6 mL) was then added and the solution was stirred for 20 min at r.t. before carbonate rac-3 (103 mg, 0.60 mmol) was added neat from a syringe. After 20 min, methyl 4-aminobutyrate hydrochloride (7; 116 mg, 0.76 mmol) and Et₃N (0.11 mL, 0.79 mmol) were added, and stirring was continued for 16 h. QuadraSil AP (~50 mg) was then added to capture Pd, and the mixture was stirred for 1 h then filtered through a short pad of Celite with EtOAc. After removal of the solvent under reduced pressure, the crude product mixture of 2 and 8 was dissolved in EtOAc (1 mL) and Et₃N (0.11 mL, 0.79 mmol), then heated at 80 °C for 20 h. The solvent was removed under reduced pressure and the crude product was purified by column chromatography [silica gel, cyclohexane–EtOAc (1:1)] to give a yellowish oil; yield: 78 mg (0.43 mmol; 72%); [α]_λ ²⁰ (c = 0.24, CHCl₃): [α]₃₆₅ –364.6, [α]₄₃₆ –206.7 °, [α]₅₄₆ –111.1, [α]₅₇₉ –96.0, [α]₅₈₉ –92.5°. ¹H NMR (400 MHz, CDCl₃): δ = 5.64 (dtd, ³ J = 15.5 Hz, ³ J = 6.3 Hz, ⁴ J = 1.3 Hz, 1 H), 5.34 (ddt, ³ J = 15.5 Hz, ³ J = 6.6 Hz, ⁴ J = 1.6 Hz, 1 H), 4.48 (Ψq, ³ J = 7.0 Hz, 1 H), 3.27 (Ψqt, ³ J = 9.6 Hz, ³ J = 7.0 Hz, 2 H), 2.45–2.35 (m, 2 H), 2.10–1.92 (m, 4 H), 1.68–1.46 (m, 2 H), 0.98 (t, ³ J = 7.5 Hz, 3 H), 0.86 (t, ³ J = 7.4 Hz, 3 H). ¹³C NMR (100 MHz, CDCl₃): δ = 174.7, 135.0, 126.6, 54.1, 42.5, 31.6, 25.5, 24.9, 18.3, 13.7, 10.8. HRMS (ESI): m/z [M + H]⁺ calcd for C₁₁H₂₀NO: 182.1539; found: 182.1540. Methyl 2-(2-Oxopyrrolidin-1-yl)butanoate (9) A round-bottomed flask was charged with a solution of 2 (105 mg, 0.58 mmol) in CH₂Cl₂ (40 mL) and a 2.50 M solution of NaOH in MeOH (3.0 mL, 7.5 mmol). The clear solution was cooled to –78 °C and a weak stream of ozone was introduced until the solution turned blue (70 min). Excess ozone was removed by introducing a weak stream of oxygen for 10 min before the solution was allowed to warm to r.t. H₂O (50 mL) was added, and the aqueous phase was extracted with CH₂Cl₂ (3 × 100 mL). The combined organic phases were dried (MgSO₄), filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography [silica gel, cyclohexane–EtOAc (1:1)] to give a yellow oil; yield: 78 mg (0.42 mmol; 73%); [α]_λ ²⁰ (c = 0.26, CHCl₃): [α]₃₆₅ –152.9, [α]₄₃₆ –87.1, [α]₅₄₆ –46.1, [α]₅₇₉ –40.0, [α]₅₈₉ –38.6. ¹H NMR (500 MHz, CDCl₃): δ = 4.69 (Ψdd, ³ J = 10.7 Hz, ⁴ J = 5.2 Hz, 1 H), 3.71 (s, 3 H), 3.52 (td, ³ J = 8.7, ⁴ J = 6.1 Hz, 1 H), 3.35 (td, ³ J = 8.8 Hz, ⁴ J = 5.5 Hz, 1 H), 2.44 (t, ³ J = 8.1 Hz, 2 H), 2.15–1.96 (m, 3 H), 1.69 (ddq, ³ J = 14.6 Hz, ³ J = 10.7 Hz, ³ J = 7.3 Hz, 1 H), 0.92 (t, ³ J = 7.4 Hz, 3 H). ¹³C NMR (125 MHz, CDCl₃): δ = 176.0, 171.7, 55.2, 52.2, 43.6, 31.0, 22.3, 18.4, 10.9. HRMS (ESI): m/z = [M + H]⁺ calcd for C₉H₁₆NO₃: 186.1124; found: 186.1127.